Fujian Aonong Biological Technology Grouporp (SHSE:603363) Other Stockholders Equity: ¥5,475 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603363 Fujian Aonong Biological Technology Group Incorp Ltd SHSE:603363
34 GF Score
Price ¥2.94
GF Value ¥1.31
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Fujian Aonong Biological Technology Grouporp Other Stockholders Equity?

Fujian Aonong Biological Technology Grouporp SHSE:603363 +0.68% 34 Other Stockholders Equity is ¥5,475 Mil as of Mar. 2026. GuruFocus rates SHSE:603363 with a GF Score™ of 34/100 and a GF Value™ of ¥1.31 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Fujian Aonong Biological Technology Grouporp's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥5,475 Mil.

Fujian Aonong Biological Technology Grouporp's quarterly Other Stockholders Equity declined from Sep. 2025 (¥5,370 Mil) to Dec. 2025 (¥114 Mil) but then increased from Dec. 2025 (¥114 Mil) to Mar. 2026 (¥5,475 Mil).

Fujian Aonong Biological Technology Grouporp's annual Other Stockholders Equity declined from Dec. 2023 (¥127 Mil) to Dec. 2024 (¥114 Mil) but then increased from Dec. 2024 (¥114 Mil) to Dec. 2025 (¥114 Mil).

Fujian Aonong Biological Technology Grouporp Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Fujian Aonong Biological Technology Grouporp's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fujian Aonong Biological Technology Grouporp Other Stockholders Equity Chart

Fujian Aonong Biological Technology Grouporp Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 258.62 124.93 126.86 113.55 114.46

Fujian Aonong Biological Technology Grouporp Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,148.41 113.12 5,369.57 114.46 5,475.02
SHSE:603363
34GF Score
Fujian Aonong Biological Technology Group Incorp Ltd SHSE:603363
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fujian Aonong Biological Technology Grouporp Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥5,475 Mil mean?
Fujian Aonong Biological Technology Grouporp (SHSE:603363) has a Other Stockholders Equity of ¥5,475 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors.
Is Fujian Aonong Biological Technology Grouporp's Other Stockholders Equity too high?
Fujian Aonong Biological Technology Grouporp's current Other Stockholders Equity is ¥5,475 Mil. Overall, Fujian Aonong Biological Technology Grouporp has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fujian Aonong Biological Technology Grouporp's Other Stockholders Equity compare to ADM and BG?
Fujian Aonong Biological Technology Grouporp's Other Stockholders Equity of ¥5,475 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Consumer Packaged Goods company?
A good Other Stockholders Equity depends on the Consumer Packaged Goods industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors. Fujian Aonong Biological Technology Grouporp's current Other Stockholders Equity is ¥5,475 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Aonong Biological Technology Grouporp stock overvalued right now?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp (SHSE:603363) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.31, compared to a current price of ¥2.94 — trading 124.4% above its estimated fair value. The current Other Stockholders Equity is ¥5,475 Mil. Fujian Aonong Biological Technology Grouporp's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Fujian Aonong Biological Technology Grouporp (SHSE:603363), the current Other Stockholders Equity is ¥5,475 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fujian Aonong Biological Technology Grouporp (SHSE:603363) Overvalued in 2026?

Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp stock appears to be overvalued. The current stock price of ¥2.94 is trading 124.4% above its estimated GF Value™ of ¥1.31. GuruFocus considers Fujian Aonong Biological Technology Grouporp to be Significantly Overvalued.

Key valuation signals for SHSE:603363:

  • Other Stockholders Equity: ¥5,475 Mil
  • GF Value™: ¥1.31 vs. price of ¥2.94 (124.4% above fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fujian Aonong Biological Technology Grouporp Business Description

Address Guanyinshan Operation Center, 12th Floor, Building 10, Siming District, Fujian Province, Xiamen, CHN, 361008
Fujian Aonong Biological Technology Group Incorp Ltd is an agricultural and animal husbandry enterprise in China. The principal business activities of the company include feed-oriented service, animal protection, pig raising, and raw material trade. In addition, the company's insurance business mainly relies on the feed marketing system throughout the country to provide downstream farmers with relevant products for disease prevention and control.
34GF Score

Get the complete analysis for SHSE:603363

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥2.94
Price
¥1.31
GF Value